Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gepadif is a hepatoprotective combination medication primarily used in the management of various liver disorders, including chronic hepatitis, liver cirrhosis, fatty liver, and toxic liver damage. Developed by Daewon Pharmaceutical, the drug contains a synergistic blend of metabolic and nutritional components: DL-carnitine hydrochloride, antitoxic liver extract, adenosine, and B-complex vitamins (riboflavin, pyridoxine, and cyanocobalamin). Its mechanism of action is multifaceted: carnitine facilitates the transport of long-chain fatty acids into mitochondria for beta-oxidation, thereby improving lipid metabolism and reducing hepatic fat accumulation; adenosine and liver extract support cellular energy production and hepatocyte regeneration; and the B-vitamins serve as essential cofactors for enzymatic reactions involved in detoxification and metabolic pathways within the liver. Gepadif is available in both oral capsule and injectable forms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gepadif.